EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?-Reference-Cited by-同舟云学术

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Published:2017-05-31 Issue:6 Volume:18 Page:1172
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Yan Ke-Sin,Lin Chia-Yuan,Liao Tan-Wei,Peng Cheng-Ming,Lee Shou-Chun,Liu Yi-Jui,Chan Wing,Chou Ruey-Hwang

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/18/6/1172/pdf

Reference149 articles.

1. EZH2: novel therapeutic target for human cancer

2. Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background

3. The SANT domain: a unique histone-tail-binding module?

4. Dominant Alleles Identify SET Domain Residues Required for Histone Methyltransferase of Polycomb Repressive Complex 2

5. Polycomb Group proteins: an evolutionary perspective

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31

2. EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review;2024-04-22

3. S-nitrosylation of EZH2 at C329 and C700 interplay with PRC2 complex assembly, methyltransferase activity, and EZH2 stability to regulate endothelial functions;2024-02-08

4. Salicylaldehyde-derived piperazine-functionalized hydrazone ligand-based Pt(ii) complexes: inhibition of EZH2-dependent tumorigenesis in pancreatic ductal adenocarcinoma, synergism with PARP inhibitors and enhanced apoptosis;Dalton Transactions;2024

5. MiR‐600 mediates EZH2/RUNX3 signal axis to modulate breast cancer cell viability and sorafenib sensitivity;Journal of Biochemical and Molecular Toxicology;2023-12-21